XstalBio Launches CentuRecon™

XstalBio Ltd has announced the launch of CentuRecon™, a new patented reconstitution technology that has the potential to revolutionize the preparation of high concentration protein solutions from dry powders and make delivery faster and safer.

Biologic drugs such as monoclonal antibodies are a major growth area for the pharmaceutical industry but their delivery by subcutaneous administration provides unique challenges.

CentuRecon™ enables dry formulations of therapeutic proteins to be prepared for injection at high concentration in minutes, rather than hours, and produces foam-free solutions that maximize the deliverable dose.

CentuRecon™ works well with standard lyophilized formulations and diluents and with normal vials, cartridges or dual-chamber syringes. It is particularly beneficial for very high concentration and/or viscous solutions that may need to be delivered with injection devices.

Medical practitioners will find CentuRecon™ straightforward and cost-effective to implement with patients benefiting from fewer injections and shorter visits.

Further developments are expected to make self-administration simpler and more convenient. To see CentuRecon in action please view the short video at: http://www.labtube.tv/playvideo.aspx?vid=155993.

XstalBio’s R&D Director, Barry D. Moore, commented “We believe CentuRecon™ is a game-changing technology; uniquely it provides a rapid, safe and reproducible method for preparing very high concentration protein solutions from dry powder formulations. We believe it will open up new clinical opportunities for biologics and become the reconstitution method of choice for R&D scientists. CentuRecon™ is a good example of how XstalBio’s R&D team are able to develop technologies that provide simple solutions to complex problems.”

This patented technology is available for licensing from XstalBio.